{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:53:47Z","timestamp":1787500427403,"version":"build-2736575974"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41443-025-01025-6","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T19:23:47Z","timestamp":1739561027000},"page":"426-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Post-finasteride syndrome - a true clinical entity?"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8431-9830","authenticated-orcid":false,"given":"Simone","family":"Cilio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2340-7343","authenticated-orcid":false,"given":"Georgios","family":"Tsampoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-4360","authenticated-orcid":false,"given":"Afonso","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-7439","authenticated-orcid":false,"given":"Pedro","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suks","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/j.1875-9114.1993.tb02739.x","volume":"13","author":"SL Sudduth","year":"1993","unstructured":"Sudduth SL, Koronkowski MJ. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy. 1993;13:309\u201325.","journal-title":"Pharmacotherapy"},{"key":"1025_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1002\/cncr.23009","volume":"110","author":"N Fleshner","year":"2007","unstructured":"Fleshner N, Zlotta AR. Prostate cancer prevention: past, present, and future. Cancer. 2007;110:1889\u201399.","journal-title":"Cancer"},{"key":"1025_CR3","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1046\/j.1365-4362.1999.00804.x","volume":"38","author":"S Brenner","year":"1999","unstructured":"Brenner S, Matz H. Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride. Int J Dermatol. 1999;38:928\u201330.","journal-title":"Int J Dermatol"},{"key":"1025_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","volume":"349","author":"IM Thompson","year":"2003","unstructured":"Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215\u201324.","journal-title":"N Engl J Med"},{"key":"1025_CR5","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192\u2013202.","journal-title":"N Engl J Med"},{"key":"1025_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.urology.2020.05.105","volume":"145","author":"Y Wu","year":"2020","unstructured":"Wu Y, Wang Y, Gu Y, Xia J, Qian Q, Hong Y. Prostate cancer risk and prognostic influence among users of 5-alpha-reductase inhibitors and alpha-blockers: a systematic review and meta-analysis. Urology. 2020;145:216\u201323.","journal-title":"Urology"},{"key":"1025_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/0019-5359.40582","volume":"62","author":"VL Kumar","year":"2008","unstructured":"Kumar VL, Wahane VD. Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate. Indian J Med Sci. 2008;62:167\u201375.","journal-title":"Indian J Med Sci"},{"key":"1025_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13741","volume":"33","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Chen C, Qu Q, Zhang C, Wang J, Fan Z, et al. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta-analysis. Dermatol Ther. 2020;33:e13741.","journal-title":"Dermatol Ther"},{"key":"1025_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/smrj.3","volume":"1","author":"L Trost","year":"2013","unstructured":"Trost L, Saitz TR, Hellstrom WJG. Side effects of 5-alpha reductase inhibitors: a comprehensive review. Sex Med Rev. 2013;1:24\u201341.","journal-title":"Sex Med Rev"},{"key":"1025_CR10","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1111\/jsm.12089","volume":"10","author":"O Canguven","year":"2013","unstructured":"Canguven O, Talib RA. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2013;10:1441.","journal-title":"J Sex Med"},{"key":"1025_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jsbmb.2014.03.012","volume":"146","author":"D Caruso","year":"2015","unstructured":"Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, et al. Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol. 2015;146:74\u20139.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1025_CR12","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","volume":"4","author":"N Mondaini","year":"2007","unstructured":"Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5\u2009mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4:1708\u201312.","journal-title":"J Sex Med"},{"key":"1025_CR13","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1001\/jamadermatol.2014.1830","volume":"150","author":"MS Irwig","year":"2014","unstructured":"Irwig MS. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatol. 2014;150:1361\u20133.","journal-title":"JAMA Dermatol"},{"key":"1025_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1557988314538445","volume":"9","author":"CA Ganzer","year":"2015","unstructured":"Ganzer CA, Jacobs AR, Iqbal F. Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health. 2015;9:222\u20138.","journal-title":"Am J Mens Health"},{"key":"1025_CR15","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.21037\/tau-22-92","volume":"11","author":"X Li","year":"2022","unstructured":"Li X, Guo Y, Lu Y, Li H, Yan S, Li H, et al. Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients. Transl Androl Urol. 2022;11:1452\u20137.","journal-title":"Transl Androl Urol"},{"key":"1025_CR16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/andr.12147","volume":"4","author":"G Chiriac\u00f2","year":"2016","unstructured":"Chiriac\u00f2 G, Cauci S, Mazzon G, Trombetta C. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology. 2016;4:245\u201350.","journal-title":"Andrology"},{"key":"1025_CR17","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4103\/aja202171","volume":"24","author":"JJ Zhang","year":"2022","unstructured":"Zhang JJ, Shi X, Wu T, Zhang MD, Tang J, Yin GM, et al. Sexual, physical, and overall adverse effects in patients treated with 5\u03b1-reductase inhibitors: a systematic review and meta-analysis. Asian J Androl. 2022;24:390\u20137.","journal-title":"Asian J Androl"},{"key":"1025_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1557988316631624","volume":"12","author":"CA Ganzer","year":"2018","unstructured":"Ganzer CA, Jacobs AR. Emotional consequences of finasteride: fool\u2019s gold. Am J Mens Health. 2018;12:90\u20135.","journal-title":"Am J Mens Health"},{"key":"1025_CR19","doi-asserted-by":"crossref","unstructured":"Asanad K, Sholklapper T, Samplaski MK, Cacciamani GE. Global online interest in finasteride sexual side effects. Int J Impot Res. 2024;36:408\u201313.","DOI":"10.1038\/s41443-022-00612-1"},{"key":"1025_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1046\/j.1365-2133.1998.02504.x","volume":"139","author":"T Sato","year":"1998","unstructured":"Sato T, Sonoda T, Itami S, Takayasu S. Predominance of type I 5alpha-reductase in apocrine sweat glands of patients with excessive or abnormal odour derived from apocrine sweat (osmidrosis). Br J Dermatol. 1998;139:806\u201310.","journal-title":"Br J Dermatol"},{"key":"1025_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/S0022-5347(01)62141-4","volume":"161","author":"PN Span","year":"1999","unstructured":"Span PN, V\u00f6ller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, et al. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol. 1999;161:332\u20137.","journal-title":"J Urol"},{"key":"1025_CR22","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0090-4295(03)00661-7","volume":"62","author":"CG Roehrborn","year":"2003","unstructured":"Roehrborn CG, Lee M, Meehan A, Waldstreicher J. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology. 2003;62:894\u20139.","journal-title":"Urology"},{"key":"1025_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1515\/hmbci-2015-0015","volume":"23","author":"AM Traish","year":"2015","unstructured":"Traish AM, Haider KS, Doros G, Haider A. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Horm Mol Biol Clin Investig. 2015;23:85\u201396.","journal-title":"Horm Mol Biol Clin Investig"},{"key":"1025_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ucl.2016.04.003","volume":"43","author":"C F\u00fcllhase","year":"2016","unstructured":"F\u00fcllhase C, Schneider MP. 5-Alpha-reductase inhibitors and combination therapy. Urol Clin North Am. 2016;43:325\u201336.","journal-title":"Urol Clin North Am"},{"key":"1025_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/sj.jidsp.5640230","volume":"4","author":"DA Whiting","year":"1999","unstructured":"Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: results of finasteride 1\u2009mg treatment of men and postmenopausal women. J Investig Dermatol Symp Proc. 1999;4:282\u20134.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"1025_CR26","first-page":"150","volume":"13","author":"DA Whiting","year":"2003","unstructured":"Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, et al. Efficacy and tolerability of finasteride 1\u2009mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol EJD. 2003;13:150\u201360.","journal-title":"Eur J Dermatol EJD"},{"key":"1025_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/1574884712666170310111125","volume":"12","author":"T Arif","year":"2017","unstructured":"Arif T, Dorjay K, Adil M, Sami M. dutasteride in androgenetic alopecia: an update. Curr Clin Pharmacol. 2017;12:31\u20135.","journal-title":"Curr Clin Pharmacol"},{"key":"1025_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.36849\/JDD.6235","volume":"22","author":"P Karagaiah","year":"2023","unstructured":"Karagaiah P, Daveluy S, Ortega-Loayza A, Gulliver W, Szepietowski J, Grabbe S, et al. Update on hormonal therapy in hidradenitis suppurativa. J Drugs Dermatol JDD. 2023;22:369\u201374.","journal-title":"J Drugs Dermatol JDD"},{"key":"1025_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s13555-023-00974-4","volume":"13","author":"M Escamilla-Cruz","year":"2023","unstructured":"Escamilla-Cruz M, Maga\u00f1a M, Escand\u00f3n-Perez S, Bello-Chavolla OY. Use of 5-alpha reductase inhibitors in dermatology: a narrative review. Dermatol Ther. 2023;13:1721\u201331.","journal-title":"Dermatol Ther"},{"key":"1025_CR30","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0090-4295(97)00091-5","volume":"49","author":"A Brufsky","year":"1997","unstructured":"Brufsky A, Fontaine-Rothe P, Berlane K, Rieker P, Jiroutek M, Kaplan I, et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology. 1997;49:913\u201320.","journal-title":"Urology"},{"key":"1025_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1464-410X.2009.08400.x","volume":"104","author":"LL Ba\u00f1ez","year":"2009","unstructured":"Ba\u00f1ez LL, Blake GW, McLeod DG, Crawford ED, Moul JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int. 2009;104:310\u20134.","journal-title":"BJU Int"},{"key":"1025_CR32","first-page":"1797","volume":"29","author":"M Tarle","year":"2009","unstructured":"Tarle M, Spajic B, Kraljic I, Kusic Z. Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendorcine differentiation and aggressive prostate cancer. Anticancer Res. 2009;29:1797\u2013801.","journal-title":"Anticancer Res"},{"key":"1025_CR33","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/jamainternmed.2019.3620","volume":"179","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Rose BS. 5\u03b1-Reductase inhibitor use in patients with prostate cancer-reply. JAMA Intern Med. 2019;179:1440\u20131.","journal-title":"JAMA Intern Med"},{"key":"1025_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00345-012-1000-4","volume":"31","author":"L Cindolo","year":"2013","unstructured":"Cindolo L, Fanizza C, Romero M, Pirozzi L, Autorino R, Berardinelli F, et al. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World J Urol. 2013;31:665\u201371.","journal-title":"World J Urol"},{"key":"1025_CR35","first-page":"56","volume":"9","author":"JM Hirshburg","year":"2016","unstructured":"Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthetic Dermatol. 2016;9:56\u201362.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"1025_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1346-8138.2011.01378.x","volume":"39","author":"A Sato","year":"2012","unstructured":"Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1\u2009mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2012;39:27\u201332.","journal-title":"J Dermatol"},{"key":"1025_CR37","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41443-022-00568-2","volume":"35","author":"N Schifano","year":"2023","unstructured":"Schifano N, Capogrosso P, Boeri L, Fallara G, Chiappini S, Rewhorn M, et al. Are finasteride-related penile curvature\/peyronie\u2019s disease adverse event reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. Int J Impot Res. 2023;35:465\u201371.","journal-title":"Int J Impot Res"},{"key":"1025_CR38","first-page":"146","volume":"18","author":"MA Gupta","year":"2020","unstructured":"Gupta MA, Vujcic B, Gupta AK. Finasteride use is associated with higher odds of obstructive sleep apnea: results from the US Food and Drug administration adverse events reporting system. Skinmed. 2020;18:146\u201350.","journal-title":"Skinmed"},{"key":"1025_CR39","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1177\/1557988317750989","volume":"12","author":"AA Walf","year":"2018","unstructured":"Walf AA, Kaurejo S, Frye CA. Research brief: self-reports of a constellation of persistent Antiandrogenic, estrogenic, physical, and psychological effects of finasteride usage among men. Am J Mens Health. 2018;12:900\u20136.","journal-title":"Am J Mens Health"},{"key":"1025_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.5534\/wjmh.180082","volume":"37","author":"HH Sung","year":"2019","unstructured":"Sung HH, Yu J, Kang SJ, Chae MR, So I, Park JK, et al. Persistent erectile dysfunction after discontinuation of 5-alpha reductase inhibitor therapy in rats depending on the duration of treatment. World J Mens Health. 2019;37:240\u20138.","journal-title":"World J Mens Health"},{"key":"1025_CR41","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1055\/s-0030-1249095","volume":"43","author":"B R\u00f6mer","year":"2010","unstructured":"R\u00f6mer B, Pfeiffer N, Lewicka S, Ben-Abdallah N, Vogt MA, Deuschle M, et al. Finasteride treatment inhibits adult hippocampal neurogenesis in male mice. Pharmacopsychiatry. 2010;43:174\u20138.","journal-title":"Pharmacopsychiatry"},{"key":"1025_CR42","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","volume":"8","author":"MS Irwig","year":"2011","unstructured":"Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8:1747\u201353.","journal-title":"J Sex Med"},{"key":"1025_CR43","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1111\/j.1743-6109.2012.02846.x","volume":"9","author":"MS Irwig","year":"2012","unstructured":"Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012;9:2927\u201332.","journal-title":"J Sex Med"},{"key":"1025_CR44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/JCP.0000000000001379","volume":"41","author":"M Pompili","year":"2021","unstructured":"Pompili M, Magistri C, Maddalena S, Mellini C, Persechino S, Baldessarini RJ. Risk of depression associated with finasteride treatment. J Clin Psychopharmacol. 2021;41:304\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"1025_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.euros.2023.04.009","volume":"52","author":"H Al Saffar","year":"2023","unstructured":"Al Saffar H, Xu J, O\u2019Brien JS, Kelly BD, Murphy DG, Lawrentschuk N. US Food and Drug Administration warning regarding finasteride and suicidal ideation: what should urologists know? Eur Urol Open Sci. 2023;52:4\u20136.","journal-title":"Eur Urol Open Sci"},{"key":"1025_CR46","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.3020","volume":"5","author":"T Kiguradze","year":"2017","unstructured":"Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, et al. Persistent erectile dysfunction in men exposed to the 5\u03b1-reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020.","journal-title":"PeerJ"},{"key":"1025_CR47","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020788s030lbl.pdf. Propecia\u2019s prescribing information. Organon & Co;2022."},{"key":"1025_CR48","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1056\/NEJMsb042458","volume":"351","author":"ME Tinetti","year":"2004","unstructured":"Tinetti ME, Bogardus STJ, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870\u20134.","journal-title":"N Engl J Med"},{"key":"1025_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1081518","volume":"11","author":"J \u00c1lvarez-G\u00e1lvez","year":"2023","unstructured":"\u00c1lvarez-G\u00e1lvez J, Ortega-Mart\u00edn E, Carretero-Bravo J, P\u00e9rez-Mu\u00f1oz C, Su\u00e1rez-Lled\u00f3 V, Ramos-Fiol B. Social determinants of multimorbidity patterns: a systematic review. Front Public Health. 2023;11:1081518.","journal-title":"Front Public Health"},{"key":"1025_CR50","unstructured":"\u2018The post-finasteride syndrome foundation\u2019. https:\/\/www.pfsfoundation.org\/. Online."},{"key":"1025_CR51","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41443-023-00762-w","volume":"36","author":"G Pezone","year":"2024","unstructured":"Pezone G, Coll\u00e0 Ruvolo C, Cilio S, Fraia A, Di Mauro E, Califano G, et al. The spreading information of YouTube videos on Phosphodiesterase 5 inhibitors: a worrisome picture from one of the most consulted internet source. Int J Impot Res. 2024;36:747\u201354.","journal-title":"Int J Impot Res"},{"key":"1025_CR52","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41443-022-00557-5","volume":"35","author":"S Cilio","year":"2023","unstructured":"Cilio S, Coll\u00e0 Ruvolo C, Turco C, Creta M, Capece M, La Rocca R, et al. Analysis of quality information provided by \u2018Dr. YouTube(TM)\u2019 on Phimosis. Int J Impot Res. 2023;35:398\u2013403.","journal-title":"Int J Impot Res"},{"key":"1025_CR53","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00228-012-1321-7","volume":"69","author":"C Biagi","year":"2013","unstructured":"Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69:237\u201344.","journal-title":"Eur J Clin Pharmacol"},{"key":"1025_CR54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamainternmed.2017.0089","volume":"177","author":"B Welk","year":"2017","unstructured":"Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5\u03b1-reductase inhibitors. JAMA Intern Med. 2017;177:683\u201391.","journal-title":"JAMA Intern Med"},{"key":"1025_CR55","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/0895-4356(94)90184-8","volume":"47","author":"EL Wynder","year":"1994","unstructured":"Wynder EL. Investigator bias and interviewer bias: the problem of reporting systematic error in epidemiology. J Clin Epidemiol. 1994;47:825\u20137.","journal-title":"J Clin Epidemiol"},{"key":"1025_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10029-022-02689-5","volume":"27","author":"WAR Zwaans","year":"2023","unstructured":"Zwaans WAR, de Bruijn JA, Dieleman JP, Steyerberg EW, Scheltinga MRM, Roumen RMH. Recall bias in pain scores evaluating abdominal wall and groin pain surgery. Hernia. 2023;27:41\u201354.","journal-title":"Hernia"},{"key":"1025_CR57","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1248\/bpb.31.1646","volume":"31","author":"Y Mukai","year":"2008","unstructured":"Mukai Y, Higashi T, Nagura Y, Shimada K. Studies on neurosteroids XXV. Influence of a 5alpha-reductase inhibitor, finasteride, on rat brain neurosteroid levels and metabolism. Biol Pharm Bull. 2008;31:1646\u201350.","journal-title":"Biol Pharm Bull"},{"key":"1025_CR58","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1111\/jsm.12269","volume":"10","author":"RC Melcangi","year":"2013","unstructured":"Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, et al. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious\/depressive symptomatology. J Sex Med. 2013;10:2598\u2013603.","journal-title":"J Sex Med"},{"key":"1025_CR59","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1530\/EC-19-0199","volume":"8","author":"RC Melcangi","year":"2019","unstructured":"Melcangi RC, Casarini L, Marino M, Santi D, Sperduti S, Giatti S, et al. Altered methylation pattern of the SRD5A2 gene in the cerebrospinal fluid of post-finasteride patients: a pilot study. Endocr Connect. 2019;8:1118\u201325.","journal-title":"Endocr Connect"},{"key":"1025_CR60","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.esxm.2016.11.001","volume":"5","author":"S Cauci","year":"2017","unstructured":"Cauci S, Chiriac\u00f2 G, Cecchin E, Toffoli G, Xodo S, Stinco G, et al. Androgen receptor (AR) gene (CAG)n and (GGN)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia. Sex Med. 2017;5:e61\u201371.","journal-title":"Sex Med"},{"key":"1025_CR61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5534\/wjmh.200012","volume":"38","author":"AM Traish","year":"2020","unstructured":"Traish AM. Health risks associated with long-term finasteride and dutasteride use: it\u2019s time to sound the alarm. World J Mens Health. 2020;38:323\u201337.","journal-title":"World J Mens Health"},{"key":"1025_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11930-018-0161-6","volume":"10","author":"AM Traish","year":"2018","unstructured":"Traish AM. The post-finasteride syndrome: clinical manifestation of drug-induced epigenetics due to endocrine disruption. Curr Sex Health Rep. 2018;10:88\u2013103.","journal-title":"Curr Sex Health Rep"},{"key":"1025_CR63","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0090-4295(02)02401-9","volume":"61","author":"H Wessells","year":"2003","unstructured":"Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61:579\u201384.","journal-title":"Urology"},{"key":"1025_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.208","volume":"4","author":"S Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect. 2016;4:e00208.","journal-title":"Pharmacol Res Perspect"},{"key":"1025_CR65","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1001\/archderm.1994.01690070062009","volume":"130","author":"C Maffei","year":"1994","unstructured":"Maffei C, Fossati A, Rinaldi F, Riva E. Personality disorders and psychopathologic symptoms in patients with androgenetic alopecia. Arch Dermatol. 1994;130:868\u201372.","journal-title":"Arch Dermatol"},{"key":"1025_CR66","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000520493","volume":"8","author":"RM Tr\u00fceb","year":"2022","unstructured":"Tr\u00fceb RM, Luu NNC, Gavazzoni Dias MFR, Dutra Rezende H. How to deal with the issues of fertility, malignancies, and the postfinasteride syndrome while prescribing finasteride for male pattern hair loss. Skin Appendage Disord. 2022;8:245\u20138.","journal-title":"Skin Appendage Disord"},{"key":"1025_CR67","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/ijt.ijt_61_18","volume":"10","author":"HD Rezende","year":"2018","unstructured":"Rezende HD, Dias MFRG, Tr\u00fceb RM. A comment on the post-finasteride syndrome. Int J Trichology. 2018;10:255\u201361.","journal-title":"Int J Trichology"},{"key":"1025_CR68","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1743-6109.2010.02157.x","volume":"8","author":"AM Traish","year":"2011","unstructured":"Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5\u03b1-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011;8:872\u201384.","journal-title":"J Sex Med"},{"key":"1025_CR69","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00345-020-03314-9","volume":"39","author":"MB Harrell","year":"2021","unstructured":"Harrell MB, Ho K, Te AE, Kaplan SA, Chughtai B. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. World J Urol. 2021;39:1233\u20139.","journal-title":"World J Urol"},{"key":"1025_CR70","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000497362","volume":"5","author":"RM Tr\u00fceb","year":"2019","unstructured":"Tr\u00fceb RM, R\u00e9gnier A, Dutra Rezende H, Gavazzoni Dias MFR. Post-finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness? Skin Appendage Disord. 2019;5:320\u20136.","journal-title":"Skin Appendage Disord"},{"key":"1025_CR71","doi-asserted-by":"publisher","DOI":"10.35946\/arcr.v40.1.05","volume":"40","author":"AC Helle","year":"2019","unstructured":"Helle AC, Watts AL, Trull TJ, Sher KJ. Alcohol use disorder and antisocial and borderline personality disorders. Alcohol Res Curr Rev. 2019;40:arcr.v40.1.05.","journal-title":"Alcohol Res Curr Rev"},{"key":"1025_CR72","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(14)61995-4","volume":"385","author":"P Tyrer","year":"2015","unstructured":"Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet Lond Engl. 2015;385:717\u201326.","journal-title":"Lancet Lond Engl"},{"key":"1025_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32356-3","volume":"13","author":"M Laanani","year":"2023","unstructured":"Laanani M, Weill A, Jollant F, Zureik M, Dray-Spira R. Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study. Sci Rep. 2023;13:5308.","journal-title":"Sci Rep"},{"key":"1025_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41585-023-00803-5","volume":"21","author":"M G\u00fcl","year":"2024","unstructured":"G\u00fcl M, Fode M, Urkmez A, Capogrosso P, Falcone M, Sarikaya S, et al. A clinical guide to rare male sexual disorders. Nat Rev Urol. 2024;21:35\u201349.","journal-title":"Nat Rev Urol"},{"key":"1025_CR75","first-page":"802","volume":"2003","author":"F Calvo","year":"2003","unstructured":"Calvo F, Karras BT, Phillips R, Kimball AM, Wolf F. Diagnoses, syndromes, and diseases: a knowledge representation problem. AMIA Annu Symp Proc AMIA Symp. 2003;2003:802.","journal-title":"AMIA Annu Symp Proc AMIA Symp"},{"key":"1025_CR76","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/jnnp.2011.241802comm","volume":"11","author":"J Stone","year":"2011","unstructured":"Stone J. We must tell our patients what is wrong with them even if we don\u2019t know why they have symptoms. Pract Neurol. 2011;11:98\u20139.","journal-title":"Pract Neurol"},{"key":"1025_CR77","doi-asserted-by":"publisher","first-page":"52","DOI":"10.7748\/ns.29.41.52.e9772","volume":"29","author":"PP Choi","year":"2015","unstructured":"Choi PP. Patient advocacy: the role of the nurse. Nurs Stand. 2015;29:52\u20138.","journal-title":"Nurs Stand"},{"key":"1025_CR78","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/jid.2010.131","volume":"130","author":"T Nijsten","year":"2010","unstructured":"Nijsten T, Bergstresser PR. Patient advocacy groups: let\u2019s stick together. J Invest Dermatol. 2010;130:1757\u20139.","journal-title":"J Invest Dermatol"},{"key":"1025_CR79","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s40618-020-01424-0","volume":"44","author":"F Borgo","year":"2021","unstructured":"Borgo F, Macandog AD, Diviccaro S, Falvo E, Giatti S, Cavaletti G, et al. Alterations of gut microbiota composition in post-finasteride patients: a pilot study. J Endocrinol Invest. 2021;44:1263\u201373.","journal-title":"J Endocrinol Invest"},{"key":"1025_CR80","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.5301\/jbm.5000095","volume":"29","author":"E Cecchin","year":"2014","unstructured":"Cecchin E, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Int J Biol Markers. 2014;29:e310\u2013316.","journal-title":"Int J Biol Markers"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01025-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01025-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01025-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T17:03:21Z","timestamp":1750698201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01025-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1038\/s41443-025-01025-6","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}